a public good project by the
Synthesis
Company
of California

© 2026

Christian Friedrich | doi.page

0 works0 citations0 h-index

Christian Friedrich

Brandenburg University of Applied Sciences(DE)Bayer (Germany)(DE)

Publications by Year

Research Areas

Diabetes Treatment and Management, Respiratory and Cough-Related Research, Peptidase Inhibition and Analysis, Asthma and respiratory diseases, Gastroesophageal reflux and treatments

Most-Cited Works

→ Contribution of Arteriogenesis and Angiogenesis to Postocclusive Hindlimb Perfusion in Mice(2002)353 cited
→ Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin *(2011)185 cited
→ Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin(2012)137 cited
→ Acute sedation-associated complications in GI endoscopy (ProSed 2 Study): results from the prospective multicentre electronic registry of sedation-associated complications(2018)129 cited
→ Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes(2010)129 cited
→ Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study(2021)96 cited

→ Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying(2008)71 cited

→ A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers(2013)64 cited

→ Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers(2011)42 cited

→ Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes(2013)42 cited